Times Square Investment Journal
  • Home
  • News
  • Company Insights
  • Stocks
  • Previews
  • Personal Finance
Select Page
Moderna will ride drug money (and your tax dollars) right out of the red

Moderna will ride drug money (and your tax dollars) right out of the red

by Suzannah Cavanaugh | Dec 16, 2020

This time last year, Moderna, Inc., was starting to look a lot like Theranos. Moderna had spent the large part of a decade selling investors on the idea of an unprecedented product—a messenger RNA drug. The company, valued at $7.5 billion, made history in December...
Moderna’s trial diversity is all for show if Black and Brown Medicaid recipients can’t afford a vaccine

Moderna’s trial diversity is all for show if Black and Brown Medicaid recipients can’t afford a vaccine

by Suzannah Cavanaugh | Oct 30, 2020

In the Covid-19 vaccine race, Moderna, Inc. made headlines last week for the representative diversity of its trial candidates.  The company touted 37% enrollment by people of color in late-stage trials, a figure that nearly mirrors the 40% of the population U.S....
Moderna says vaccine produces antibodies in seniors, pushes ahead in Warp Speed race

Moderna says vaccine produces antibodies in seniors, pushes ahead in Warp Speed race

by Suzannah Cavanaugh | Oct 2, 2020

Moderna Inc. announced Tuesday that its Covid-19 vaccine candidate had generated levels of virus-neutralizing antibodies in older adults on par with those produced in younger trial participants, a crucial step towards approval. The early-stage result gives Moderna a...

Investment Journal

Welcome to Investment Journal, a site covering the world of business right from Times Square. The site is produced by reporters at the New York City News Service and the Craig Newmark Graduate School of Journalism at CUNY. Email your comments to greg.david@journalism.cuny.edu.
  • Facebook
  • Twitter
  • Google
  • RSS

Designed by Elegant Themes | Powered by WordPress